MDWD — MediWound Ltd.

Nasdaq · Materials · Chemicals · CIK 1593984 ·
Last close
$16.68
Market Cap
$214.38M
52W High
$18.13
52W Low
$14.90
ADV30
60,560
Next earnings
2026-05-27
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 1,867,000 278,000 -7,813,000 -7,183,000 86,255,000 4,799,000 42,623,000
Sep 2025 5,429,000 896,000 -6,525,000 -2,652,000 94,423,000 44,267,000
Jun 2025 5,708,000 1,342,000 -5,716,000 -13,318,000 67,001,000 46,882,000
Mar 2025 3,955,000 738,000 -5,225,000 -726,000 69,016,000 37,744,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-16,121,000
Investing CF
$-17,950,000
Financing CF
$29,620,000
CapEx
$-5,505,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.10
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-228,925,000
Inventory
$4,093,000
Receivables
$2,372,000
ST Investments
$48,341,000
EBIT TTM
$-23,330,000
Pretax Income TTM
$-23,710,000
Interest Exp TTM
$7,564,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$16,959,000
EBITDA
$-24,280,000
Free Cash Flow
$-15,578,875
Enterprise Value
$169,900,672
Total Cash
$53,140,000
Total Debt
$8,775,000
Shares Out
12,852,255
Trailing EPS
$-2.10
Book Value
$3.40
ROE
-63.9%
ROA
-19.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 16,959,000 -25,279,000 -23,879,000 86,255,000 42,623,000 -16,121,000
Dec 2024 20,222,000 -19,382,000 -30,224,000 73,496,000 42,343,000 -13,624,000
Dec 2023 18,686,000 -15,501,000 -6,716,000 66,459,000 34,864,000 -10,465,000
Dec 2022 26,496,000 -7,661,000 -19,599,000 50,016,000 39,102,000 -11,885,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.17

Peers — same industry

TickerNameMarket CapLastDaily %
PTNM Pitanium Ltd $207.93M $10.39
ACB AURORA CANNABIS INC $204.58M $3.46
CDXS CODEXIS, INC. $236.33M $2.60
FF FutureFuel Corp. $176.77M $4.03
AMTX AEMETIS, INC $175.92M $2.50

News headlines (Yahoo Finance, 1h cache)

NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates
2026-05-15 21:55 · Yahoo
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
2026-05-14 23:40 · Yahoo
Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates
2026-05-13 21:15 · Yahoo
Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates
2026-05-07 21:55 · Yahoo
MediWound to Report First Quarter 2026 Financial Results
2026-05-07 12:00 · Yahoo
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
2026-04-13 11:30 · Yahoo
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
2026-04-07 11:00 · Yahoo
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
2026-04-02 19:26 · Yahoo
MediWound Q4 Earnings Call Highlights
2026-03-06 03:10 · Yahoo
MediWound Files Annual Report on Form 20-F
2026-03-05 21:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.